Kaplan-Maier estimates of OS and PFS in patients receiving tandem auto/allo HCT. (A) OS (blue lines) in 102 patients who completed the tandem auto/alloHCT (solid line) and in the subgroup of 73 patients who received autoHCT within 10 months from treatment beginning (dotted line) and PFS (red lines) in 102 patients who completed the tandem auto/alloHCT (solid line) and in the subgroup of 73 patients who received autoHCT within 10 months from treatment beginning (dotted line). (B) Cumulative incidence of disease progression or relapse (blue lines) in 102 patients who completed the tandem auto/alloHCT (solid line) and in the subgroup of 73 patients who received autoHCT within 10 months from treatment beginning (dotted line) and NRM (red lines) in 102 patients who completed the tandem auto/alloHCT (solid line) and in the subgroup of 73 patients who received autoHCT within 10 months from treatment beginning (dotted line). (C-E) Kaplan Maier estimates of PFS. (C) Disease status at autoHCT: CR/VGPR (blue line, n = 26), PR (red line, n = 50), < PR (green line, n = 26). (D) Disease status at alloHCT: CR/VGPR (blue line, n = 43), PR (red line, n = 41), < PR (green line, n = 18). (E) Karnofsky performance status at alloHCT: more than 90% (red line, n = 66), less than 90% (blue line, n = 33). (F) Overall survival from disease relapse or progression in 51 patients who completed the tandem auto/alloHCT (solid line) and in the subgroup of 36 patients who received autoHCT within 10 months from treatment beginning (dotted line).